18-10-2018 | Melanoma | News | Article
Neoadjuvant checkpoint blockade investigated in high-risk melanoma
In patients with high-risk resectable melanoma, neoadjuvant treatment with the combination of nivolumab and ipilimumab is associated with high response rates but also considerable toxicity, while single-agent nivolumab has better tolerability but is less efficacious, trial results show.
17-05-2018 | Oncology | News | Article
Cancer immunotherapy efficacy may vary by sex
The magnitude of the survival benefit associated with immune checkpoint inhibitor treatment appears to be sex dependent, with women benefiting less than men, according to a meta-analysis published in The Lancet Oncology.
Pipette_rack with samples/© science photo / Fotoli, Clear vial_injection 2/© Anton Gvozdikov / Fotolia, Cancer cell/© xrender / Getty Images / iStoc, Male & female symbols/© seraficus / Getty Images / iStock